C

CytomX Therapeutics
D

CTMX

2.13500
USD
-0.03
(-1.16%)
مغلق
حجم التداول
0
الربح لكل سهم
0
العائد الربحي
-
P/E
4
حجم السوق
336,357,228
أصول ذات صلة
A
APA
-0.195
(-1.06%)
18.175 USD
C
CHX
-0.135
(-0.54%)
24.660 USD
C
CLNE
0.10000
(5.71%)
1.85000 USD
F
FPAY
-0.02500
(-1.98%)
1.24000 USD
I
IAG
-0.38500
(-5.04%)
7.25000 USD
N
NGD
-0.08000
(-1.62%)
4.84500 USD
المزيد
الأخبار المقالات

العنوان: CytomX Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designedto take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.